Diabetic Retinopathy News and Research

RSS
In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
Study: Lower-income students in China have better vision compared to middle-class counterparts

Study: Lower-income students in China have better vision compared to middle-class counterparts

Reversing effects of early stage age-related macular degeneration may be possible

Reversing effects of early stage age-related macular degeneration may be possible

National Centre for Healthcare Photonics to be located in North East of England

National Centre for Healthcare Photonics to be located in North East of England

Welch Allyn, LKC Technologies sign distribution agreement for RETeval DR screening device

Welch Allyn, LKC Technologies sign distribution agreement for RETeval DR screening device

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Fenofibrate benefits in diabetic retinopathy mediated through PPARα

Eylea receives Health Canada approval for treatment of CRVO and DME

Eylea receives Health Canada approval for treatment of CRVO and DME

Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Eye screenings of underserved populations reveal one in five has early stage diabetic retinopathy

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

Endothelin gene expression linked to vision loss in premature babies

Endothelin gene expression linked to vision loss in premature babies

New model of primary care could improve health of patients with type 2 diabetes

New model of primary care could improve health of patients with type 2 diabetes

UVA Center for Telehealth receives 2014 Governor's Technology Award

UVA Center for Telehealth receives 2014 Governor's Technology Award

‘Reassuring’ findings on microvascular risk in diabetic statin users

‘Reassuring’ findings on microvascular risk in diabetic statin users

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

New research shows statins could reduce common diabetes complications

New research shows statins could reduce common diabetes complications

Professor receives award for development of anti-angiogenic therapy for retinal disease

Professor receives award for development of anti-angiogenic therapy for retinal disease

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

Using molecular imaging probes diabetic retinopathy can be detected at molecular level

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Macular ischaemia, retinal thinning linked to reduced visual function in diabetic retinopathy

Macular ischaemia, retinal thinning linked to reduced visual function in diabetic retinopathy

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.